2018 Drug Development Pipeline Review for Optic Nerve Disorders (Optic Neuropathy, Glaucoma, LHON and Optic Neuritis)

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]

SOURCE Research and Markets

DUBLIN, Nov 9, 2018 /PRNewswire/ —

The “Optic Nerve Disorders Drug Development Pipeline Review, 2018” report has been added to ResearchAndMarkets.com’s offering.

Research and Markets Logo

This report provides an overview of the pipeline landscape for disorders of the optic nerve, the bundle of nerve fibers that transmits visual information from the eye to the brain. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for optic neuropathy, glaucoma, Leber’s hereditary optic neuropathy (LHON) and optic neuritis, and features dormant and discontinued products.

  • Optic Neuropathy – There are 10 products in development for this indication.
  • Glaucoma – There are 13 products in development for this indication.
  • LHON – There are 16 products in development for this indication.
  • Optic Neuritis – There are 12 products in development for this indication.

Molecular targets acted on by products in development for optic nerve disorders include kinases, growth factors and cannabinoid receptors. Companies operating in this pipeline space include NicOx SA Regeneron Pharmaceuticals and Amgen


  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Key Topics Covered

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Optic Nerve Disorders Report Coverage
2.2 Optic Neuropathy – Overview
2.3 Glaucoma – Overview
2.4 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Overview
2.5 Optic Neuritis – Overview

3 Therapeutics Development
3.1 Optic Neuropathy
3.2 Glaucoma
3.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
3.4 Optic Neuritis

4 Therapeutics Assessment
4.1 Optic Neuropathy
4.2 Glaucoma
4.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
4.4 Optic Neuritis

5 Companies Involved in Therapeutics Development
5.1 Optic Neuropathy
5.2 Glaucoma
5.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
5.4 Optic Neuritis

6 Dormant Projects
6.1 Optic Neuropathy
6.2 Glaucoma
6.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
6.4 Optic Neuritis

7 Discontinued Products
7.1 Optic Neuropathy
7.2 Glaucoma
7.3 Optic Neuritis

8 Product Development Milestones
8.1 Optic Neuropathy
8.2 Glaucoma
8.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
8.4 Optic Neuritis

Companies Featured

  • AC Immune SA
  • Aerie Pharmaceuticals Inc
  • Alkeus Pharmaceuticals Inc
  • Allergan Plc
  • Altacor Ltd
  • Amarantus Bioscience Holdings Inc
  • Amgen Inc
  • Annexon Inc
  • Astellas Pharma Inc
  • Bactevo Ltd
  • Bial – Portela & Ca SA
  • BioAxone BioSciences Inc
  • Bionure Farma SL
  • Biovista Inc
  • Can-Fite BioPharma Ltd
  • Cellix Bio Pvt Ltd
  • Certa Therapeutics Pty Ltd
  • Chong Kun Dang Pharmaceutical Corp
  • Coma
  • Commence Bio Inc
  • D. Western Therapeutics Institute Inc
  • Disarm Therapeutics Inc
  • Dompe Farmaceutici SpA
  • Elsalys Biotech SA
  • EyePoint Pharmaceuticals Inc
  • Eyevensys SAS
  • Fortify Therapeutics Inc
  • Fortress Biotech Inc
  • GenSight Biologics SA
  • Gene Signal International SA
  • Glaukos Corp
  • Graybug Vision Inc
  • Han Wha Pharma Co Ltd
  • Handok Inc
  • HitGen LTD
  • ID Pharma Co Ltd
  • InMed Pharmaceuticals Inc
  • Inspyr Therapeutics Inc
  • Ironwood Pharmaceuticals Inc
  • Isarna Therapeutics GmbH
  • Ixchel Pharma LLC
  • Khondrion BV
  • Kowa Co Ltd
  • Kukje Pharmaceutical Industry Co Ltd
  • Laboratorios SALVAT SA
  • Laboratorios Sophia SA de CV
  • Lee’s Pharmaceutical Holdings Ltd
  • Lipocure Ltd
  • Meta-IQ ApS
  • MimeTech Srl
  • Mitobridge Inc
  • Mitochon Pharmaceuticals Inc
  • Mitotech SA
  • Nemus Bioscience Inc
  • Neurim Pharmaceuticals Ltd
  • Neuritis
  • NicOx SA
  • NoNO Inc
  • Novaliq GmbH
  • Novartis AG
  • Ocular Therapeutix Inc
  • Oculis ehf
  • Ohr Pharmaceutical Inc
  • Oncolys BioPharma Inc
  • Pivot Pharmaceuticals Inc
  • Profarma
  • Q BioMed Inc
  • ReNetX Bio
  • Regenera Pharma Ltd
  • Santen Pharmaceutical Co Ltd
  • Santhera Pharmaceuticals Holding AG
  • Senju Pharmaceutical Co Ltd
  • Shire Plc
  • Spark Therapeutics Inc
  • Stealth BioTherapeutics Inc
  • Sun Pharma Advanced Research Company Ltd
  • Sylentis SAU
  • Taejoon Pharm Co Ltd
  • Teijin Pharma Ltd
  • TikoMed AB
  • Unity Biotechnology Inc

For more information about this report visit https://www.researchandmarkets.com/research/3sq3hm/2018_drug?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:http://www.prnewswire.com/news-releases/2018-drug-development-pipeline-review-for-optic-nerve-disorders-optic-neuropathy-glaucoma-lhon-and-optic-neuritis-300747537.html

©2017 PR Newswire. All Rights Reserved.